Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks to buy with highest upside potential. Guggenheim lifted the price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $36 from $30 on May 26 and maintained a Buy rating on the shares, updating its model after the recent fiscal Q4 earnings and pipeline updates. The stock also received a rating update from Citi on May 21. The firm lifted the price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $42 from $35 and maintained a Buy rating on the shares. Citi stated that it sees further share upside on the company’s second half of 2026 data catalysts, and the stock remains a top pick at the firm following the IMVT-1402 data.

WhyRoivant Sciences Ltd. (ROIV) Surged On Thursday

In its financial results for fiscal Q4 and full year ended March 31, 2026, Roivant Sciences Ltd. (NASDAQ:ROIV) reported that it has consolidated cash, cash equivalents, and marketable securities of $4.3 billion. It further stated that research and development expenses rose by $53.7 million to $198.9 million for the three months ended March 31, 2026, compared to $145.2 million for the three months ended March 31, 2025.

Roivant Sciences Ltd. (NASDAQ:ROIV) is involved in the biopharmaceutical business and engages in the development of transformative medicine. The company’s product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aim to treat psoriasis, thyroid eye disease, atopic dermatitis, and other illnesses.

While we acknowledge the risk and potential of ROIV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ROIV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1